Analysis of lipoprotein subclasses of family with familial hypertriglyceridemia based on VAP method

doi:10.3969/j.issn.1674-8115.2022.04.010

Abstract

Abstract: Objective

·To analyze the characteristics of lipoprotein subclasses of family members with familial hypertriglyceridemia (FHTG).

Methods

·A FHTG family with 13 members meeting the diagnostic criteria of the FHTG family was collected at the First Hospital of Lanzhou University. They were divided into the high triacylglycerol (TAG) group (7 persons) and the control group (6 persons) according to whether the level of TAG of the family members increased (≥2.26 mmol/L). Through the face-to-face investigation, age, gender, height, weight, body mass index (BMI), waist circumference, living habits and medical history and other general information of each member were collected. Based on the survey results, a family tree was drawn. After 8?12 h in abrosia, peripheral venous blood samples of the family members were collected for biochemical testing. The vertical auto profile (VAP) was used to determine the serum lipoprotein subclasses of the study subjects, including TAG, total cholesterol, low-density lipoprotein cholesterol (LDL-C), low-density lipoprotein (LDL), very low-density lipoprotein (VLDL), very low-density lipoprotein 3 (VLDL₃), high-density lipoprotein cholesterol (HDL-C), high-density lipoprotein 2 (HDL₂), high-density lipoprotein 3 (HDL₃), intermediate-density lipoprotein, remnant-like lipoprotein particle, lipoprotein a and non-high-density lipoprotein. The LDL pattern was obtained by VAP method based on the analysis of LDL max time value. The vertical lipoprotein profile (VLP) was used to determine the serum low-density lipoprotein particle (LDL-P) of the study subjects. The levels of lipoprotein subclasses between the control group and the high TAG group were compared by independent sample t test.

Results

·Compared with the control group, the high TAG group in FHTG pedigree had remarkably higher levels of height, weight, BMI and waist circumference (P=0.022, P=0.000, P=0.001, P=0.000). There was statistical significance in gender difference between the two groups (P=0.029), but there was no significant difference in age (P=0.561). Compared with the control group, the high TAG group had remarkably higher levels of TAG, VLDL, VLDL₃and LDL-P (P=0.003, P=0.033, P=0.020, P=0.043), and remarkably lower level of HDL-C, HDL₂ and HDL₃ (P=0.000, P=0.001, P=0.001). The LDL pattern in the high TAG group was small and dense, while the LDL pattern in the normal control group was mixed or large and sparse. There were no significant differences between other indicators.

Conclusions

·In addition to the TAG and HDL-C commonly used in clinical practice, VLDL, VLDL₃, LDL-P, small and dense LDL, HDL₂ and HDL₃ are expected to become the indicators for FHTG diagnosis and treatment.

Key words: familial hypertriglyceridemia (FHTG), vertical auto profile (VAP), lipoprotein subclasses, triacylglycerol (TAG), cardiovascular disease

CLC Number:

R589.2

HE Zhijie, HE Jinchun, ZHANG Yanpei, WANG Yaodong, WANG Zhanke. Analysis of lipoprotein subclasses of family with familial hypertriglyceridemia based on VAP method[J]. Journal of Shanghai Jiao Tong University (Medical Science), 2022, 42(4): 482-489.

Figures/Tables 7

TrendMD

References 23

1	LAHOZ C, MOSTAZA J M. Familial hypertriglyceridemia/polygenic hypertrigliceridemia[J]. Clin Investig Arterioscler, 2021, 33(Suppl 2): 37-42.
2	CARRASQUILLA G D, CHRISTIANSEN M R, KILPELÄINEN T O. The genetic basis of hypertriglyceridemia[J]. Curr Atheroscler Rep, 2021, 23(8): 39.
3	CRUZ-BAUTISTA I, HUERTA-CHAGOYA A, MORENO-MACÍAS H, et al. Familial hypertriglyceridemia: an entity with distinguishable features from other causes of hypertriglyceridemia[J]. Lipids Health Dis, 2021, 20(1): 14.
4	诸骏仁, 高润霖, 赵水平, 等. 中国成人血脂异常防治指南(2016年修订版)[J]. 中国循环杂志, 2016, 31(10): 937-953.
	ZHU J R, GAO R L, ZHAO S P, et al. The guidelines for prevention and treatment of dyslipidemia in Chinese adults (revised edition 2016)[J]. Chin J Cardiol, 2016, 44(10): 833-853.
5	KULKARNI K R. Cholesterol profile measurement by vertical auto profile method[J]. Clin Lab Med, 2006, 26(4): 787-802.
6	刘维娟, 周珊珊, 何津春, 等. 家族性高三酰甘油血症诊断标准及鉴别诊断[J]. 医学综述, 2014, 20(17): 3089-3091.
	LIU W J, ZHOU S S, HE J C, et al. Diagnostic criteria and differential diagnosis of familial hypertriglyceridemia[J]. Med Recapitulate, 2014, 20(17): 3089-3091.
7	梁纯子, 朱满, 涂建成. VAP检测血浆脂蛋白亚组分的新进展及应用分析[J]. 检验医学, 2019, 34(1): 76-81.
	LIANG C Z, ZHU M, TU J C, Research progress of VAP in determining plasma lipoprotein subfractions[J]. Lab Med, 2019, 34(1): 76-81.
8	PAN L, YANG Z H, WU Y, et al. The prevalence, awareness, treatment and control of dyslipidemia among adults in China[J]. Atherosclerosis, 2016, 248: 2-9.
9	张娜, 张海燕, 郭晓红, 等. 中国近十年急性胰腺炎病因变化特点的Meta分析[J]. 中华消化病与影像杂志(电子版), 2016, 6(2): 71-75.
	ZHANG N, ZHANG H Y, GUO X H, et al. Changes of etiology in acute pancreatitis in recent 10 years in China: Meta-analysis[J]. Chin J Digest Med Imageol (Electronic Edition), 2016, 6(2): 71-75.
10	OLESEN S S, HARAKOW A, KROGH K, et al. Hypertriglyceridemia is often under recognized as an aetiologic risk factor for acute pancreatitis: a population-based cohort study[J]. Pancreatology, 2021, 21(2): 334-341.
11	SHAIK A, ROSENSON R S. Genetics of triglyceride-rich lipoproteins guide identification of pharmacotherapy for cardiovascular risk reduction[J]. Cardiovasc Drugs Ther, 2021, 35(3): 677-690.
12	中华医学会心血管病学分会循证医学评论专家组, 中国老年学学会心脑血管病专业委员会. 甘油三酯增高的血脂异常防治中国专家共识[J]. 中华心血管病杂志, 2011, 39(9): 793-796.
	Expert Group of Evidence-based Medicine Review of Cardiovascular Credit Association of Chinese Medical Association, Professional Committee of Cardiovascular and Cerebrovascular Diseases of Chinese Gerontology Society. Consensus of Chinese experts on the prevention and treatment of dyslipidemia caused by elevated triglycerides[J]. Chin J Cardiol, 2011, 39(9): 793-796.
13	FARUKHI Z, MORA S. Is it time to abandon fasting for routine lipid testing? [J]. Clevel Clin J Med, 2017, 84(12): 919-922.
14	JUSTESEN J M, ALLIN K H, SANDHOLT C H, et al. Interactions of lipid genetic risk scores with estimates of metabolic health in a Danish population[J]. Circ Cardiovasc Genet, 2015, 8(3): 465-472.
15	REINER Ž. Triglyceride-rich lipoproteins and novel targets for anti-atherosclerotic therapy[J]. Korean Circ J, 2018, 48(12): 1097-1119.
16	LANGLOIS M R, CHAPMAN M J, COBBAERT C, et al. Quantifying atherogenic lipoproteins: current and future challenges in the era of personalized medicine and very low concentrations of LDL cholesterol. A consensus statement from EAS and EFLM[J]. Clin Chem, 2018, 64(7): 1006-1033.
17	HALLÉN J, SREEHARAN N. Development of triglyceride-lowering drugs to address residual cardiovascular risk: strategic and clinical considerations[J]. Eur Heart J Cardiovasc Pharmacother, 2018, 4(4): 237-242.
18	NORDESTGAARD B G. Triglyceride-rich lipoproteins and atherosclerotic cardiovascular disease: new insights from epidemiology, genetics, and biology[J]. Circ Res, 2016, 118(4): 547-563.
19	ALLAIRE J, VORS C, COUTURE P, et al. LDL particle number and size and cardiovascular risk: anything new under the sun? [J]. Curr Opin Lipidol, 2017, 28(3): 261-266.
20	MARTIN S S, KHOKHAR A A, MAY H T, et al. HDL cholesterol subclasses, myocardial infarction, and mortality in secondary prevention: the Lipoprotein Investigators Collaborative[J]. Eur Heart J, 2015, 36(1): 22-30.
21	ZHAO M, GUO Z H, JIA G W, et al. Influencing factors of coronary artery Stenosis in patients with stable coronary heart disease and a correlation analysis[J]. Am J Transl Res, 2021, 13(8): 9522-9529.
22	SINGH A, PUHAN R, PRADHAN A, et al. Small dense low-density lipoprotein for risk prediction of acute coronary syndrome[J]. Cardiol Res, 2021, 12(4): 251-257.
23	YU Y, WANG L, ZHU X, et al. Sodium ozagrel and atorvastatin for type 2 diabetes patients with lacunar cerebral infarction[J]. World J Diabetes, 2021, 12(12): 2096-2106.

Item	Control group （n＝6）	High TAG group （n＝7）	t/χ² value	P value
Age/year	61.17±17.15	54.57±21.73	0.599	0.561
Gender （male/female）/n（%）	1 （16.7）//5 （83.3）	6 （85.7）/1 （14.3）	3.731	0.029
Height/cm	164.67±4.13	179.14±12.62	-2.676	0.022
Weight/kg	57.67±5.89	88.43±10.15	-6.520	0.000
BMI/（kg·m^-2）	21.30 ± 2.25	27.64± 2.58	-4.680	0.001
Waist circumference/cm	73.22±5.33	103.14±9.37	-6.898	0.000

Item	Control group （n＝6）	High TAG group （n＝7）	t/χ² value	P value
Age/year	61.17±17.15	54.57±21.73	0.599	0.561
Gender （male/female）/n（%）	1 （16.7）//5 （83.3）	6 （85.7）/1 （14.3）	3.731	0.029
Height/cm	164.67±4.13	179.14±12.62	-2.676	0.022
Weight/kg	57.67±5.89	88.43±10.15	-6.520	0.000
BMI/（kg·m^-2）	21.30 ± 2.25	27.64± 2.58	-4.680	0.001
Waist circumference/cm	73.22±5.33	103.14±9.37	-6.898	0.000

Item	Control group （n＝6）	High TAG group （n＝7）	t value	P value
TC/（mmol·L^-1）	5.08±0.77	4.89±0.72	0.467	0.650
TAG/（mmol·L^-1）	0.88±0.47	4.16±1.98	-3.945	0.002
HDL-C/（mmol·L^-1）	1.64± 0.18	1.01± 0.28	4.680	0.001
LDL-C/（mmol·L^-1）	3.18±0.77	3.28±0.53	-0.291	0.776
apo AⅠ/（g·L^-1）	1.75±0.19	1.31±0.24	3.602	0.004
apo B/（g·L^-1）	0.91±0.19	1.01±0.17	-0.991	0.343
Lp （a）/（mg·dL^-1）	20.05±22.09	9.91±6.37	1.166	0.268

Item	Control group （n＝6）	High TAG group （n＝7）	t value	P value
TC/（mmol·L^-1）	5.08±0.77	4.89±0.72	0.467	0.650
TAG/（mmol·L^-1）	0.88±0.47	4.16±1.98	-3.945	0.002
HDL-C/（mmol·L^-1）	1.64± 0.18	1.01± 0.28	4.680	0.001
LDL-C/（mmol·L^-1）	3.18±0.77	3.28±0.53	-0.291	0.776
apo AⅠ/（g·L^-1）	1.75±0.19	1.31±0.24	3.602	0.004
apo B/（g·L^-1）	0.91±0.19	1.01±0.17	-0.991	0.343
Lp （a）/（mg·dL^-1）	20.05±22.09	9.91±6.37	1.166	0.268

Item	Control group （n＝6）	High TAG group （n＝7）
Pattern B/n（%）	0 （0）	7 （100）
Pattern A/B/n（%）	2 （33.3）	0 （0）
Pattern A/n（%）	4 （66.7）	0 （0）